ReviewAdvances in experimental medicine and biology2025
The C-Type Lectin Receptors.
Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The C-type lectin AcCTL5 fromVirulence · 2026Article
- SpEchinoidin, a C-type lectin and a member of an expanded CTL family, is up-regulated by phagocytes in sea urchins responding to immune challenge.Developmental and comparative immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C-type lectins (CTLs) form a broad and diverse protein superfamily with the ability to identify a wide array of ligands with their characteristic C-type lectin-like domains (CTLDs), thus governing a broad spectrum of physiological functions. CTLD-containing proteins (CTLDcps) are now classified into 17 groups based on their phylogeny and overall domain organization. While much research has centered on the role of C-type lectins in innate and adaptive antimicrobial immune responses, their significance extends further. They are increasingly acknowledged for their significant involvement in cancer biology. It has been evident that the CLR signaling can wield dual effects akin to a double-edged sword across various microbial or oncogenic scenarios. Consequently, the therapeutic potential of both agonists and antagonists targeting CLR signaling is now surfacing as innovative strategies. The growing body of evidence highlighting the indispensable role of C-type lectin receptors (CTLR) in numerous biological processes underscores the necessity for a deeper comprehension of their functional capabilities in both immune defense and disease contexts.
Indexed as
Identifiers
40622541What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.